Floatz logo

FALLYPRIDE

Primary Progressive Aphasia

University of ChicagoSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Primary Progressive Aphasia cohort.

Same molecule, other indications

FALLYPRIDE is also rated in:

Alzheimer DementiaDormant
BB
Indicative ·
67 / 100
View asset →
Essential TremorDormant
BB
Indicative ·
64 / 100
View asset →
Breast CancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →